BGPT: Paper Review: Divergent effects of dithiocarbamates on AP-1-containing and AP-1-less NFAT sites

Explore by Goal

Quick Explanation Copied

Core finding (from this paper)

PDTC shows divergent control of NFAT enhancers in Jurkat T cells: it enhances the AP-1–containing IL-2 NFAT enhancer output but abolishes the AP-1–less IL-4 NFp enhancer output; calcineurin overexpression restores IL-4 NFp activity.

Long Explanation

Paper Review (visual-first): Divergent effects of dithiocarbamates on AP-1-containing and AP-1-less NFAT sites

Published: 1999 (Eur. J. Immunol., issue page range 1194–1201).

Evidence note about the plotted “%” values

The IL-6 statement is explicit (“completely suppressed”); the IL-4 statement is explicit (“about 60% reduction”); the IL-2 magnitude is described qualitatively (“strongly enhanced”) without a numeric fold-change in the provided full text excerpt, so its bar is an ordinal mapping, not a precise measurement.

PDTC reduces IL-4 NFp reporter output and calcineurin co-expression prevents this reduction, while simultaneously enhancing IL-2 NFAT reporter activity under PDTC.

PDTC inhibited IL-6-O_B NF-κB DNA binding and enhanced formation of the IL-2 NFAT complex (AP-1-containing), while inhibiting IL-4 NFp complex formation (AP-1-less).

Mechanistic wiring diagram (evidence-tagged)

What the paper actually demonstrated (and how)

1) PDTC changes DNA–protein complex formation in a site-specific way

Jurkat nuclear extracts were tested by EMSA using probes for IL-6 κB (NF-κB), collagenase TRE–AP-1, IL-4 NFp (AP-1–less NFAT site), and IL-2 distal NFAT (AP-1–containing NFAT complex). The same stimulus (PMA/PHA) produces detectable complexes for all sites; PDTC inhibits NF-κB binding and produces opposite effects on AP-1-containing versus AP-1-less NFAT sites.

2) The IL-2 NFAT complex correlates with increased c-Jun (AP-1 component)

Western blotting in nuclear extracts shows that PDTC increases c-Jun nuclear expression while decreasing NF-κB p50/p65 nuclear levels upon PMA/PHA activation. Supershift/competition indicates NFATc is present in both IL-4 NFp and IL-2 NFAT complexes, while an AP-1 (c-Jun) supershift is reported for IL-2 NFAT but not IL-4 NFp (supporting AP-1 presence specifically in the IL-2 complex).

3) Calcineurin function is positioned as the critical node for IL-4 NFp inhibition

The authors co-transfected IL-4 NFp-CAT or IL-2 NFAT-β-gal reporters with a constitutively active calcineurin construct (CN-A). PDTC suppresses IL-4 NFp output under PMA/PHA, but calcineurin overexpression “completely” prevents this inhibition; calcineurin also boosts IL-2 NFAT output.

Cytokine output direction under PDTC (text-extracted)

For 5 µM PDTC pretreatment in PMA/PHA-activated fresh human T lymphocytes (per discussion/conclusion excerpt), IL-4 secretion is reported as totally inhibited and IFN-γ as reduced by ~50%, while GM-CSF is unaffected.

Skeptical critique: where the evidence is strong vs uncertain

Specificity of PDTC: PDTC is described as an antioxidant/metal chelator and known to affect multiple pathways beyond a single transcription factor axis; the mechanistic attribution to calcineurin is supported by the CN-A rescue, but PDTC could still influence additional steps (e.g., upstream signaling, kinase/phosphatase balance) that indirectly change NFAT output.
Single primary cell model for mechanistic readouts: binding and reporter assays are performed in Jurkat T cells; while the paper mentions fresh human T lymphocytes for cytokine directionality, most mechanistic dissection is in a single cell line, which may not generalize to diverse T cell subsets or physiological stimulation contexts.
Binding-to-transcription mapping: EMSA demonstrates changes in DNA–protein complex formation; reporter assays support corresponding changes in enhancer output. However, enhancer function in vivo also depends on chromatin context, co-regulators, and mRNA processing; the reporter approach uses simplified enhancer repeats and does not fully reconstruct genomic chromatin constraints.
“Divergence” interpretation depends on AP-1 presence: the study’s central claim is that AP-1-containing vs AP-1-less NFAT sites respond oppositely to PDTC. That is consistent with the c-Jun association and the different enhancer outputs, but alternative explanations remain (e.g., PDTC effects on other NFAT cofactors, or differences in cofactor recruitment kinetics).

External corroboration (context, not proof)

The broader idea that calcineurin/NFAT pathway activation can reshape transcriptional programs diverging from other transcription factor axes (and that immunosuppressive drugs perturb these outcomes) is consistent with later work linking calcineurin activity to divergent regulation of T cell genes in a context-dependent manner.

Additionally, PDTC/dithiocarbamates have been reported to block NF-κB activation while influencing AP-1 activity in other cell systems, aligning with the paper’s observed PDTC pattern (↓NF-κB, ↑AP-1-associated complex formation).

Link out to author-specific reviews on BGPT

Feedback:

Updated: March 29, 2026